Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL): Managing New and Current Patients, Reducing Risk

BIA-ALCL is a rare type of lymphoma associated with textured, but not smooth, breast implants. As of April 2020, there were approximately 800 BIA-ALCL cases worldwide, including 33 BIA-ALCL–related deaths. When detected early, BIA-ALCL is curable in most patients with proper treatment. However, although BIA-ALCL has been recognized by the World Health Organization since 2016, many primary care practitioners (PCPs) and plastic surgeons are not fully aware of how to detect and diagnose BIA-ALCL, as well as recommended treatment strategies for this disease. There is therefore an unmet need for continuing education to better educate PCPs and plastic surgeons on how to diagnose, stage, and optimally treat BIA-ALCL, as well as how to better educate their patients about the importance of early detection and appropriate treatment.

Learning Objectives


At the conclusion of this activity, participants should be able to:

  • Describe possible complications of textured breast implants, including the symptoms and relative risk of BIA-ALCL and benefits of early identification and treatment
  • Create protocols for appropriate management of asymptomatic patients with textured implants as well as surgical protocols to reduce risk of BIA-ALCL
  • Devise an effective plan to educate and communicate with patients who have implants about BIA-ALCL, its early signs and symptoms, and the association of early detection with prognosis

Acknowledgement of Commercial Support


This activity is supported by an educational grant from AbbVie Inc.